LILLY (LLY.N) Trading
Live Chart & Price Analysis
View the real-time LILLY (LLY.N) quote and decide if you want to go long or short. Find insights, analysis, the latest news and other information to help you with your trading.
$1,157.89
-1.97%33.33% buyers
Followers
650
Annual change
52.25%
Daily price range:
Low
1,152.39
High
1,211.37
Trade LLY
CFD trading involves risk
LLY live price
Live Chart
Past performance is not a reliable indicator of future results.
Should you buy or sell LILLY right now?
Based on NAGA Sentiment¹, 33.33% are buying LILLY and 66.67% are selling LILLY right now. However, opening a long or short position now depends on your risk tolerance, investment horizon, and LILLY market outlook.
Selling
66.67%
33.33%
Buying
LILLY price analysis
The price of LILLY today, as of September 30, 2026, was $1157.89. That's down -2.00% from last session's LILLY closing price. The LILLY price is rising this week. Compared to last week, the rate of LILLY is up 0.50%, and it's down -0.70% from one month ago.
The 52-week LILLY price high is $1289.25, while the 52-week LILLY price low is $787.24.
Year to date, LILLY price is up 38.50% from the beginning of the year and has had a return of 38.50% in the last 12 months.
Low$1152.39
Day's Range
Low$787.24
52w Range-0.6%
1h
-2.0%
24h
+0.5%
7d
+1.4%
14d
-0.7%
30d
+38.5%
1y
LILLY trading insights
The crowd feels NEGATIVE about LILLY, with a HIGH volume of news backing the NEGATIVE sentiment score². At the start of today's LILLY trading session, the sentiment signal³ is BEARISH, indicating whether the LILLY price is more likely to increase or decrease today and in the following days.
The level of news⁴ backing the sentiment score is HIGH, indicating how confident the markets are to buy LILLY right now. The LOW subjectivity⁵ indicates that the LILLY price is UNDERVALUED.
Sentiment Signal
Bearish
Next update: Oct 1, 12:30
Sentiment Score
Negative
37 / 100
Subjectivity
Low Subjectivity
21 / 100
Confidence Index
High
Discover key LILLY trends with NAGA Insights
What am I Missing?
Make informed decisions based on real-time data, expert analysis, and powerful research tools from TipRanks.
Access advanced LILLY charting, technical analysis, and live market data from TradingView.
Get AI-powered LILLY trade signals, in-depth market analysis, and technical strategy insights from Trading Central.
CFD trading involves risk
How to trade LILLY with leverage?
Trade LILLY if you want flexibility to speculate on its price movements in both directions. With CFDs, you can open a buy position (go long) if you think the LILLY price will rise, or you can open a sell position (go short) if you believe the LILLY price will fall.
You won’t need to commit to the full value of the position (see the required margin below), but bear in mind that leverage can increase both your profits and losses.
If you want to speculate on LILLY price, search for LILLY CFD. Then click on the "LILLY" symbol to view the chart and other insights before placing your trade. Also, review "LILLY" contract specification to be aware of all the LILLY CFD trading conditions.
trading conditions:
Platform
MT5
Platform spreads
Live: 7.4824
Ticker#LLY.N
Margin (%)*
Volume step
Lot value
Minimum trade size
Maximum trade size
Commission0.00%
Monthly price change (%)0.05%
Annual price change (%)52.25%
Digits
Tick value0.009
Trading Hours & FeesCFD trading involves risk
About LILLY
LLY
Lilly
CFD
-1.97%
$1,166.34
$1,157.89
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LILLY price forecast, news, and analysis
Discover the latest news that can influence LILLY’s earnings sentiment and LILLY forecast and price predictions.
Positive
Eli Lilly's Ebglyss Phase 3 Success Highlights Growth Potential for LLY
01/10/2026/00:56
Neutral
Lilly's Foundayo Shows Cardiovascular Safety, Sustained A1C And Weight Benefits In ACHIEVE-4
30/09/2026/23:59
Positive
Lilly's Foundayo Demonstrates Cardiovascular Safety In Landmark Diabetes Study
30/09/2026/22:40
FAQs about LILLY trading
The price of LILLY today, as of September 30, 2026, was 1157.89. That's down -2.00% from the previous session's LILLY closing price.
IMPORTANT NOTICE: The content presented in the instrument page is only for informational, educational and support purposes. The material presented, including analyses, sentiment, consensus, prices, opinions or other content, is not an investment recommendation or information that recommends or suggests an investment strategy, nor is it included in the scope of investment advice. NAGA will not accept liability for any loss or damage, including but not limited to any loss of profits, that may arise directly or indirectly from the use of or reliance on the information contained in this page. NAGA is not responsible for the actions or omissions of the client, especially for the acquisition or disposal of financial instruments, made based on the information contained in this page. Past performance is not necessarily indicative of future results, and anyone acting on this information does so at their own risk. ¹ NAGA sentiment reflects the positions held by active NAGA users who currently maintain open trades in a specific instrument. This information is provided for indicative purposes only and should not be interpreted as investment advice or a recommendation to trade. ² ³ ⁴ ⁵ The sentiment dashboard is provided by Trading Central. Sentiment insights and market views are based on available data and do not guarantee future performance.
Need Help? Visit our Help Section
Download NAGA Trader
Download NAGA Trader
Click the QR code to enlarge
Copyright © 2026 – All rights reserved.
NAGA is a trademark of The NAGA Group AG, a German based FinTech company publicly listed on the Frankfurt Stock Exchange | WKN: A41YCM | ISIN: DE000A41YCM0.
The website is operated by JME Financial Services (Pty) Ltd an authorised Financial Services Provider, regulated by the Financial Sector Conduct Authority in South Africa under license no. 37166. JME Financial Services (Pty) Ltd is located at Suite 10, 21 Lighthouse Rd 201 Beacon Rock, Umhlanga Rocks, Kwa-Zulu Natal, 4320, South Africa.
JME Financial Services (Pty) Ltd acts as an intermediary between the investor and NAGA Capital Ltd, the counterparty to the contract for difference purchased by the Investor via Naga.com/za. NAGA Capital Ltd is authorised and regulated by the Financial Services Authority Seychelles (FSA) under licence No. SD026. NAGA Capital Ltd is the principal to the CFD purchased by investors on this website. Other group entities: NAGA Markets Europe LTD which is authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC) under licence No. 204/13.
RISK WARNING: Derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how derivatives work and whether you can afford to take the high risk of losing your money. The value of financial products can increase as well as decrease over time, depending on the value of the underlying securities and market conditions. Illustrations, forecasts or hypothetical data are not guaranteed and are provided for illustrative purposes only. JME Financial Services (Pty) Ltd does not render advice in respect of the CFD’s offered on this website. Before making an investment decision, you should rely on your own assessment. The Company’s disclaimer, conflict of interest policy are available on legal documents section.